TrialBMC musculoskeletal disorders2011

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

Bart J F van den Bemt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.